Oxford Nanopore Technologies PLC

ONT London Stock Exchange Healthcare & Biotech United Kingdom
1.20 £
2.59 %

Company developing innovative portable DNA sequencing for applications in healthcare, research, and biotechnology.

Price history of Oxford Nanopore Technologies PLC
Price history of Oxford Nanopore Technologies PLC

Performance & Momentum

6 Months 5.72 %
1 Year 5.57 %
3 Years 50.08 %
5 Years 80.42 %

Strategic Analysis

Oxford Nanopore Technologies PLC • 2026

Oxford Nanopore is positioned in next-generation DNA sequencing with a portable, flexible approach geared toward field use. Its model is based on the commercialization of platforms and consumables for research, applied genomics and molecular diagnostics, with strong differentiation through mobility and ease of use.

Strengths
  • Portable sequencing technology that is differentiated from heavier, laboratory-based solutions
  • Exposure to structurally growing markets driven by genomics, diagnostics and biotechnology
  • Potential for recurring revenue through consumables and the expansion of use cases
Weaknesses
  • Still fragile market profile, with an underlying trend that has remained negative over several years
  • Dependence on commercial adoption and on the ability to turn technological innovation into profitable growth
Momentum

Momentum appears to have improved significantly in the short term, with a visible rebound that contrasts with an underlying trend that remains very defensive over longer horizons. For investors, this points to a speculative stock in a technical recovery phase, but whose credibility still depends on confirmation of sustained commercial execution rather than a simple catch-up move.

Similar stocks to Oxford Nanopore Technologies PLC

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone